Development of a Second-Generation, In Vivo Chemical Probe for PIKfyve

We optimized our highly potent and cell-active chemical probe for phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), SGC-PIKFYVE-1, resulting in compounds with improved potency and demonstrated stability. Use of an in-cell, kinome-wide selectivity panel allowed for confirmation of excellent in-cel...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2025-01
Main Authors: Min, Sophia M, Bashore, Frances M, Smith, Jeffery L, Havener, Tammy M, Howell, Stefanie, Li, Haoxi, Couñago, Rafael M, Popov, Konstantin I, Axtman, Alison D
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c1831-387a958dd03a6426ccb4a8781ab428e393bcc899ef3b97ff9daa4b338a9a11883
container_end_page
container_issue
container_start_page
container_title Journal of medicinal chemistry
container_volume
creator Min, Sophia M
Bashore, Frances M
Smith, Jeffery L
Havener, Tammy M
Howell, Stefanie
Li, Haoxi
Couñago, Rafael M
Popov, Konstantin I
Axtman, Alison D
description We optimized our highly potent and cell-active chemical probe for phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), SGC-PIKFYVE-1, resulting in compounds with improved potency and demonstrated stability. Use of an in-cell, kinome-wide selectivity panel allowed for confirmation of excellent in-cell selectivity of our lead compound, , and another promising analogue, . Evaluation of the pharmacokinetic (PK) profiles of these two compounds revealed that both are well tolerated systemically and orally bioavailable. Coupled with its subnanomolar cellular potency and impressive selectivity in cells, the long half-life of makes it an ideal candidate for the evaluation of the consequences of PIKfyve inhibition . PIKfyve inhibition has been investigated clinically for indications including rheumatoid arthritis, Crohn's disease, COVID-19, and ALS using a single compound (apilimod), supporting the development of orthogonal PIKfyve inhibitors with stability.
doi_str_mv 10.1021/acs.jmedchem.4c02531
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3158100983</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3158100983</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1831-387a958dd03a6426ccb4a8781ab428e393bcc899ef3b97ff9daa4b338a9a11883</originalsourceid><addsrcrecordid>eNo9kE9PAjEUxBujEUS_gTE9enCx7etCezQoSCSRxD_Xptt9jUt2t9gCCd_eNaCnObyZN5kfIdecDTkT_N66NFw1WLovbIbSMZEDPyF9nguWScXkKekzJkQmRgJ65CKlFWMMuIBz0gOtQOkR65PpI-6wDusG2w0Nnlr6hi60ZTbDFqPdVKG9o_OWfla7QCddVeVsTZcxFEh9iHQ5f_H7HV6SM2_rhFdHHZCP6dP75DlbvM7mk4dF5rgCnoEaW52rsmRgR1KMnCukVWPFbSGFQtBQOKe0Rg-FHnuvS2tlAaCstpwrBQNye_i7juF7i2ljmio5rGvbYtgmAzxXnLFuXmeVB6uLIaWI3qxj1di4N5yZX4KmI2j-CJojwS52c2zYFt3tP_SHDH4APt9ucw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3158100983</pqid></control><display><type>article</type><title>Development of a Second-Generation, In Vivo Chemical Probe for PIKfyve</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Min, Sophia M ; Bashore, Frances M ; Smith, Jeffery L ; Havener, Tammy M ; Howell, Stefanie ; Li, Haoxi ; Couñago, Rafael M ; Popov, Konstantin I ; Axtman, Alison D</creator><creatorcontrib>Min, Sophia M ; Bashore, Frances M ; Smith, Jeffery L ; Havener, Tammy M ; Howell, Stefanie ; Li, Haoxi ; Couñago, Rafael M ; Popov, Konstantin I ; Axtman, Alison D</creatorcontrib><description>We optimized our highly potent and cell-active chemical probe for phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), SGC-PIKFYVE-1, resulting in compounds with improved potency and demonstrated stability. Use of an in-cell, kinome-wide selectivity panel allowed for confirmation of excellent in-cell selectivity of our lead compound, , and another promising analogue, . Evaluation of the pharmacokinetic (PK) profiles of these two compounds revealed that both are well tolerated systemically and orally bioavailable. Coupled with its subnanomolar cellular potency and impressive selectivity in cells, the long half-life of makes it an ideal candidate for the evaluation of the consequences of PIKfyve inhibition . PIKfyve inhibition has been investigated clinically for indications including rheumatoid arthritis, Crohn's disease, COVID-19, and ALS using a single compound (apilimod), supporting the development of orthogonal PIKfyve inhibitors with stability.</description><identifier>ISSN: 0022-2623</identifier><identifier>ISSN: 1520-4804</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/acs.jmedchem.4c02531</identifier><identifier>PMID: 39838960</identifier><language>eng</language><publisher>United States</publisher><ispartof>Journal of medicinal chemistry, 2025-01</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1831-387a958dd03a6426ccb4a8781ab428e393bcc899ef3b97ff9daa4b338a9a11883</cites><orcidid>0000-0003-4241-9873 ; 0000-0003-4779-9932 ; 0000-0003-1847-5090 ; 0000-0002-4613-0498 ; 0000-0001-9840-2996</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39838960$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Min, Sophia M</creatorcontrib><creatorcontrib>Bashore, Frances M</creatorcontrib><creatorcontrib>Smith, Jeffery L</creatorcontrib><creatorcontrib>Havener, Tammy M</creatorcontrib><creatorcontrib>Howell, Stefanie</creatorcontrib><creatorcontrib>Li, Haoxi</creatorcontrib><creatorcontrib>Couñago, Rafael M</creatorcontrib><creatorcontrib>Popov, Konstantin I</creatorcontrib><creatorcontrib>Axtman, Alison D</creatorcontrib><title>Development of a Second-Generation, In Vivo Chemical Probe for PIKfyve</title><title>Journal of medicinal chemistry</title><addtitle>J Med Chem</addtitle><description>We optimized our highly potent and cell-active chemical probe for phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), SGC-PIKFYVE-1, resulting in compounds with improved potency and demonstrated stability. Use of an in-cell, kinome-wide selectivity panel allowed for confirmation of excellent in-cell selectivity of our lead compound, , and another promising analogue, . Evaluation of the pharmacokinetic (PK) profiles of these two compounds revealed that both are well tolerated systemically and orally bioavailable. Coupled with its subnanomolar cellular potency and impressive selectivity in cells, the long half-life of makes it an ideal candidate for the evaluation of the consequences of PIKfyve inhibition . PIKfyve inhibition has been investigated clinically for indications including rheumatoid arthritis, Crohn's disease, COVID-19, and ALS using a single compound (apilimod), supporting the development of orthogonal PIKfyve inhibitors with stability.</description><issn>0022-2623</issn><issn>1520-4804</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNo9kE9PAjEUxBujEUS_gTE9enCx7etCezQoSCSRxD_Xptt9jUt2t9gCCd_eNaCnObyZN5kfIdecDTkT_N66NFw1WLovbIbSMZEDPyF9nguWScXkKekzJkQmRgJ65CKlFWMMuIBz0gOtQOkR65PpI-6wDusG2w0Nnlr6hi60ZTbDFqPdVKG9o_OWfla7QCddVeVsTZcxFEh9iHQ5f_H7HV6SM2_rhFdHHZCP6dP75DlbvM7mk4dF5rgCnoEaW52rsmRgR1KMnCukVWPFbSGFQtBQOKe0Rg-FHnuvS2tlAaCstpwrBQNye_i7juF7i2ljmio5rGvbYtgmAzxXnLFuXmeVB6uLIaWI3qxj1di4N5yZX4KmI2j-CJojwS52c2zYFt3tP_SHDH4APt9ucw</recordid><startdate>20250122</startdate><enddate>20250122</enddate><creator>Min, Sophia M</creator><creator>Bashore, Frances M</creator><creator>Smith, Jeffery L</creator><creator>Havener, Tammy M</creator><creator>Howell, Stefanie</creator><creator>Li, Haoxi</creator><creator>Couñago, Rafael M</creator><creator>Popov, Konstantin I</creator><creator>Axtman, Alison D</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4241-9873</orcidid><orcidid>https://orcid.org/0000-0003-4779-9932</orcidid><orcidid>https://orcid.org/0000-0003-1847-5090</orcidid><orcidid>https://orcid.org/0000-0002-4613-0498</orcidid><orcidid>https://orcid.org/0000-0001-9840-2996</orcidid></search><sort><creationdate>20250122</creationdate><title>Development of a Second-Generation, In Vivo Chemical Probe for PIKfyve</title><author>Min, Sophia M ; Bashore, Frances M ; Smith, Jeffery L ; Havener, Tammy M ; Howell, Stefanie ; Li, Haoxi ; Couñago, Rafael M ; Popov, Konstantin I ; Axtman, Alison D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1831-387a958dd03a6426ccb4a8781ab428e393bcc899ef3b97ff9daa4b338a9a11883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Min, Sophia M</creatorcontrib><creatorcontrib>Bashore, Frances M</creatorcontrib><creatorcontrib>Smith, Jeffery L</creatorcontrib><creatorcontrib>Havener, Tammy M</creatorcontrib><creatorcontrib>Howell, Stefanie</creatorcontrib><creatorcontrib>Li, Haoxi</creatorcontrib><creatorcontrib>Couñago, Rafael M</creatorcontrib><creatorcontrib>Popov, Konstantin I</creatorcontrib><creatorcontrib>Axtman, Alison D</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Min, Sophia M</au><au>Bashore, Frances M</au><au>Smith, Jeffery L</au><au>Havener, Tammy M</au><au>Howell, Stefanie</au><au>Li, Haoxi</au><au>Couñago, Rafael M</au><au>Popov, Konstantin I</au><au>Axtman, Alison D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of a Second-Generation, In Vivo Chemical Probe for PIKfyve</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J Med Chem</addtitle><date>2025-01-22</date><risdate>2025</risdate><issn>0022-2623</issn><issn>1520-4804</issn><eissn>1520-4804</eissn><abstract>We optimized our highly potent and cell-active chemical probe for phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), SGC-PIKFYVE-1, resulting in compounds with improved potency and demonstrated stability. Use of an in-cell, kinome-wide selectivity panel allowed for confirmation of excellent in-cell selectivity of our lead compound, , and another promising analogue, . Evaluation of the pharmacokinetic (PK) profiles of these two compounds revealed that both are well tolerated systemically and orally bioavailable. Coupled with its subnanomolar cellular potency and impressive selectivity in cells, the long half-life of makes it an ideal candidate for the evaluation of the consequences of PIKfyve inhibition . PIKfyve inhibition has been investigated clinically for indications including rheumatoid arthritis, Crohn's disease, COVID-19, and ALS using a single compound (apilimod), supporting the development of orthogonal PIKfyve inhibitors with stability.</abstract><cop>United States</cop><pmid>39838960</pmid><doi>10.1021/acs.jmedchem.4c02531</doi><orcidid>https://orcid.org/0000-0003-4241-9873</orcidid><orcidid>https://orcid.org/0000-0003-4779-9932</orcidid><orcidid>https://orcid.org/0000-0003-1847-5090</orcidid><orcidid>https://orcid.org/0000-0002-4613-0498</orcidid><orcidid>https://orcid.org/0000-0001-9840-2996</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2025-01
issn 0022-2623
1520-4804
1520-4804
language eng
recordid cdi_proquest_miscellaneous_3158100983
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
title Development of a Second-Generation, In Vivo Chemical Probe for PIKfyve
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T07%3A37%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20a%20Second-Generation,%20In%20Vivo%20Chemical%20Probe%20for%20PIKfyve&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Min,%20Sophia%20M&rft.date=2025-01-22&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/acs.jmedchem.4c02531&rft_dat=%3Cproquest_cross%3E3158100983%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1831-387a958dd03a6426ccb4a8781ab428e393bcc899ef3b97ff9daa4b338a9a11883%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3158100983&rft_id=info:pmid/39838960&rfr_iscdi=true